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Background: The standard treatment for patients with chronic hepatitis C (CHC), pegylated interferon-α (PEG-IFN)
plus ribavirin (RBV) does not provide a sustained virological response (SVR) in all patients. Genetic variations at the
interleukin 28B (IL-28B) locus are important in predicting outcome following therapy in CHC patients.
Results: We investigated the role of IL28B variations (rs8099917) in response to PEG-IFN-α/RBV treatment and
evaluated its association with the risk of the null virological response (NVR) and relapse (REL) in different viral
genotypes. We found that the overall distributions of the genotype among the SVR, NVR, and REL groups were
significantly different (P<0.001). Patients with the TG genotype had an increased risk of NVR and REL (OR=6.45 95%
CI =2.88–14.47, P<0.001 for NVR; OR=2.51, 95% CI =1.29–4.86, P=0.006 for REL, respectively), and patients with the
GG genotype had a further increased risk of NVR and REL (OR=12.04, 95% CI =3.21–45.13, P<0.001 for NVR; ,
OR=4.30, 95% CI =1.21–15.13, P=0.017 for REL, respectively). G variant genotypes (TG+GG) also had an increased risk
of NVR and REL, and there was a significant trend for a dose-effect of G allele on the risk of NVR and REL (P<0.05).
The SVR rate in TT higher than in TG+GG was more pronounced in those patients infected with non-G1 compared
to the patients infected with G1. The treatment response did differ based on the rs8099917 genotype in patients
with different viral genotypes, compared with patients infected with the non-G1, the G1 infected patients had an
increased risk of NVR and REL (OR=2.03 95% CI =1.03–4.01, P=0.04 for NVR and OR=2.58, 95% CI =1.35–4.94,
P=0.004 for REL, respectively). Moreover, multivariate regression analysis show that the rs8099917 G allele was the
only independent factor significantly associated with a NVR and REL.
Conclusion: This study suggests that host genetic polymorphisms rs8099917 in the vicinity of IL-28B is the most
important predictor of treatment response of PEG-IFN-α/RBV for HCV patients in China.
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Hepatitis C is a global health problem which affects a sig-
nificant proportion of the world, accounting for 3% of
the total population [1,2]. There are approximately 40
million people in China infected with the hepatitis C
virus (HCV), accounting for 1.7% of the Chinese popula-
tion. Presently, the standard treatment for patients with
chronic hepatitis C (CHC) is pegylated interferon-α* Correspondence: gaozl33@gmail.com
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reproduction in any medium, provided the or(PEG-IFN- α) and ribavirin (RBV) [3,4]. In the United
States and Europe, 42%–52% of patients with HCV geno-
type 1 achieve a sustained virological response (SVR) [5].
However, the response rate was much higher in China
when treated with the corresponding regimen [6,7]. It
has long been suspected that host genetic factors are key
determinants for the treatment of CHC.
Recently, some genome-wide association studies
(GWAS) have identified that the single nucleotide poly-
morphism (SNP) rs8099917 effectively predicts responses
to IFN therapy [8-11]. Importantly, those studies used
similar genotyping techniques and analytical methods
and included different ethnic groups, the outcome was
definite. The SNP is located on chromosome 19q13,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(IL-28B) gene that encodes type III interferon (IFN-λ3)
[12,13]. The IL-28B genotype frequency reportedly varies
according to ethnicity and is associated with viral
responses to PEG-IFN-α/RBV therapy against HCV
genotype 1 (G1)-infected patients from North America,
Europe, and Japan [14-16]. No systematic explanation
exists for the viral genotype-specific differences which
exist in response to treatment. The importance of theses
IL28B variants for Chinese patients and for the non-1
viral genotype (non-G1) remains unknown. If non-G1
viral genotypes have a proclivity to infect patients with a
specific IL28B genotype, it would be useful to predict an
individual’s response either before treatment or during
the early stages of treatment. Some patients have with-
drawn from IFN-based therapy because of undesirable
side effects [17]. Prediction of the probable effectiveness
of IFN therapy therefore plays an essential role in a clin-
ical setting. Adverse drug reactions can be avoided in
patients unlikely to benefit from treatment, and the sub-
stantial cost of PEG-IFN-α/RBV treatment could be
reduced [11]. The aim of this study was to determine the
influence of the rs8099917 variations in the response of




The clinical characteristics and the treatment responses
of the 236 infected with HCV included in this study are
presented in Table 1. Overall, there was no significant
difference in our study cohort among the SVR, NVR,
and REL respect to age, gender, BMI, liver enzyme levels,
infection time and HCV RNA viral load(all P > 0.05).
However, the HCV genotype frequencies were signifi-
cantly different among the SVR, NVR, and REL groupsTable 1 Demographic and biochemical features of patients
Variable SVR
Total no. of subjects 131
Age (years) 44.96 ± 10.85
Gender: male (%) 79(60.3%)
BMI 22.17 ± 2.94
ALT(U/L) 60(33–119)
AST(U/L) 49(34–120)
Platelet count (×104/mm3) 17.48 ± 5.42
HCV genotype 1 (%) 58(44.3%)
Fibrosisa: F3-F4 (%) 16(29.1%)
Infection timeb(year) 5(2–13)
Virus load (log IU/ml) 6.18 ± 1.17
a: 101 patients had ultrasound-guided percutaneous liver biopsies, all biopsy specim
factors to initial anti-viral therapy.(P= 0.006). Of the CHC patients, 53%(126/236) were
infected with HCV viral G1, 47%(110/236) were infected
with HCV viral non-G1 (13% with genotype 2, 4% with
genotype 3, and 30% with genotype 6,respectively). The
proportion of the G1 genotype in NVR and REL groups
was higher than in SVR group (61.7%, 67.2%, and 44.3%,
respectively). Moreover, severe fibro sis was significantly
associated with NVR or REL (P= 0.007).
The distribution and association of IL28B genotype with
response to PEG-IFN-α/RBV treatment
The genotype and allele distributions of the IL28B
rs8099917 polymorphisms are summarized in Table 2.
The overall distributions of the genotype among the
SVR, NVR, and REL groups were significantly different
(P < 0.001). The frequencies of TT was significantly
higher in the patients achieved SVR than in those
achieved NVR and REL (65.6% in SVR, 21.3% in NVR,
41.4% in REL, respectively). Logistic regression analysis
showed that compared with patients with the TT geno-
type, TG genotype had an increased risk of NVR and
REL (odds ratio [OR] = 6.45 95% confidence interval
[CI] =2.88–14.47, P < 0.001 for NVR; OR = 2.51, 95%
CI =1.29–4.86, P = 0.006 for REL, respectively), GG
genotype had a further increased risk of NVR and
REL (OR = 12.04 95% CI =3.21–45.13, P < 0.001 for
NVR; OR=OR=4.30, 95% CI =1.21–15.13, P=0.017 for
REL, respectively). Complicated TG with GG genotype to-
gether, G variant genotypes (TG+GG) also had an
increased risk of NVR and REL, and there was a significant
trend for a dose-effect of G allele on the risk of NVR and
REL. Moreover, compared with T allele carriers, G allele
carriers had a significantly higher risk of NVR and REL
(OR = 3.73, 95% CI =2.24–6.21, P < 0.001 for NVR;
OR = 2.23, 95% CI =1.37–3.45, P=0.001 for REL,
respectively).NVR Rel P value
47 58
40.87 ± 14.18 44.76 ± 10.97 0.106
36(76.6%) 35(60.3%) 0.116
22.01 ± 2.64 22.77 ± 3.43 0.352
57(38–89) 59(27–95) 0.315
49(35–69) 45(28–73) 0.219
17.16 ± 6.40 18.42 ± 11.35 0.641
29(61.7%) 39(67.2%) 0.006
16(66.7%) 10 (45.5%) 0.007
5(3–12) 6(3–11) 0.952
6.08 ± 0.82 6.12 ± 1.05 0.617
ens were used for the histologic diagnosis b:duration of exposure on risk
Table 2 The distribution and association of IL28B genotype with response to PEG-IFN-α/RBV treatment
SVR NVR Rel NVR vs. SVR P value Rel vs. SVR P value
N,% N,% N,% OR(95%CI) OR(95%CI)
SNP genotype
TT 86(65.6%) 10(21.3%) 24(41.4%) 1.0 (Reference) 1.0 (Reference)
TG 40(30.5%) 30(63.8%) 28(48.3%) 6.45(2.88–14.47) <0.001 2.51(1.29–4.86) 0.006
GG 5(3.8%) 7(14.9%) 6(10.3%) 12.04(3.21–45.13) <0.001 4.30(1.21–15.13) 0.017
TG+GG 45(34.4%) 37(78.3%) 34(58.6%) 7.07(3.22–15.52) <0.001 2.71(1.44–5.11) 0.002
Allele
T allele 212(80.9%) 50(53.2%) 76(65.5%) 1.0 (Reference) 1.0 (Reference)
G allele 50(19.1%) 44(46.8%) 40(34.5%) 3.73(2.24–6.21) <0.001 2.23(1.37–3.45) 0.001
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different HCV genotypes
When the treatment response was stratified according to
the viral genotype, there were more non-G1 patients
with the rs8099917 TT genotype with a SVR compared
to the number of patients with the rs8099917 TG+GG
genotype. Compared with patients infected with G1, the
SVR rate in TT higher than in TG+GG was more pro-
nounced in those patients infected with non-G1 (77.9%
in TT and 39.4% in TG+GG for non-G1 versus 60.5%
in TT and 38.6% in TG+GG for G1). Moreover, the
treatment response did differ based on the rs8099917
genotype in patients with different viral genotypes. Com-
pared with patients infected with non-G1, G1 infected
patients had an increased risk of NVR and REL
(OR = 2.03 95% CI =1.03–4.01, P = 0.04 for NVR;
OR=2.58, 95% CI =1.35–4.94, P=0.004 for REL, respect-
ively) (Table 3).
Factors associated with NVR and REL
To further examine the relative contribution of factors
associated with NVR and REL, we used a logistic regres-
sion model. When adjusting for HCV genotype, baseline
levels of HCV RNA load and ALT, baseline age, gender,
infection time, fibrosis, the G allele of rs8099917 was the
most significant factor for predicting NVR and REL
(OR= 14.02, 95% CI = 3.35–58.65, P < 0.0001 for NVR
versus SVR and OR= 2.27, 95% CI = 1.13–4.58, P= 0.022
for REL versus SVR, respectively). This result suggests
that the rs8099917 G allele may was a most importantTable 3 Treatment response according to IL28B genotype in
Genotype SVR NVR REL
N,% N,% N,%
Non-G1 73(66.4%) 18(16.3%) 19(17.3%)
TT 60(77.9%) 7(9.1%) 10(13.0%)
TG+GG 13(39.4%) 11(33.3%) 9(27.3%)
G1 58(46.0%) 29(23.0%) 39(31.0%)
TT 26(60.5%) 3(7.0%) 14(32.6%)
TG+GG 32(38.6%) 26(31.3%) 25(30.1%)predictive factor for NVR or REL before PEG-IFN-α/
RBV therapy (Table 4).
Discussion
In the present study, we showed the existence of differ-
ent rs8099917 genotype frequencies and HCV viral gen-
otypes in patients with different treatment responses.
Carriers with the rs8099917 TT genotype and non-G1
HCV genotype had a high chance of achieving SVR and
a lower likelihood of either NVR or REL. In contrast,
carriers with the rs8099917 TG/GG genotype and G1
HCV genotype had a high risk of NVR or REL. Combin-
ing the two pretreatment predictors, IL-28B genetic var-
iants and HCV genotype accurately predicted treatment
efficacy of every patient before therapy. This strategy
could conceivably play a very important role in the HCV
treatment decision-making process because of the high
frequency of the favorable allele and the high frequency
of SVR in China [18]. This study is anticipated to open a
new window for genotype-based personalized medicine
for Chinese patients with CHC.
Nowadays, several studies have reported that genetic
variants near IL-28B are associated with response to
treatment of chronic HCV infection with a combination
of PEG-IFN and RBV [8,9,11,19]. The IL-28B gene allele
frequency was reported to vary according to ethnicity. In
the current study, we found that G variants (TG+GG)
carriers had a significantly higher risk of NVR and REL.
Moreover, logistic regression analysis showed that G al-
lele was an independent predictive factors of NVR anddifferent HCV genotypes
P value NVR vs. SVR Rel vs. SVR
OR(95%CI) OR(95%CI)




Table 4 Factors associated with NVR and REL by multivariate logistic regression
Factors NVR vs. SVR REL vs. SVR
Odds ratio 95% CI P value Odds ratio 95% CI P value
G allele 14.02 3.35–58.65 <0.0001 2.27 1.13–4.58 0.022
Age 0.98 0.94–1.01 0.228 0.98 0.95–1.02 0.292
BMI 1.01 0.88–1.17 0.861 1.05 0.94–1.17 0.437
Gender 1.96 0.77–4.98.49 0.158 0.91 0.44–1.90 0.806
Infection time(year) 1.01 0.92–1.10 0.892 1.00 0.94–1.07 0.945
HCV genotype 0.77 0.31–1.95 0.587 1.85 0.86–3.98 0.113
Virus load 0.83 0.57–1.20 0.318 0.81 0.60–1.10 0.174
ALT 1.00 0.99–1.01 0.087 0.99 0.98–1.00 0.048
Fibrosis 3.02 0.91–10.01 0.070 1.70 0.48–6.01 0.409
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patients in previous studies [11,20]. These results may
provide useful information for a personalized treatment
regimen.
In the current study, it is noteworthy that a high rate
of Chinese patients with the TT genotype of rs8099917
attained a SVR. Similarly, Tanaka Y, et al. reported that
rs8099917 had a strong association with response to
therapy and the TT genotype of the rs8099917 poly-
morphism was associated with a high SVR rate [11].
Suppiah et al. also reported that the highest rate of SVR
was in the group of patients with the TT genotype of
rs8099917 and that the presence of the G allele was the
most powerful predictive factor for NVR [9] . Overall,
our results were in agreement with the results reported
by Suppiah et al. and Tanaka et al. Logistic regression
model identified the rs8099917 G allele as the most sig-
nificant factor for predicting NVR (OR= 14.02), whereas
the prediction of REL using the SNP had lower statistical
power (OR= 2.27) compared to NVR prediction, indicat-
ing that these SNPs are strongly associated with the out-
come of NVR. The REL patients with the TT genotype
might be able to achieve a SVR following prolonged
therapy with PEG-IFN/RBV. Clinically, many factors,
such as age, gender, pretreatment HCV RNA levels,
higher pretreatment AST levels, liver fibrosis status, and
insulin resistance are important factors in the outcome
of PEG-IFN-α/RBV therapy [5,21-23]. Nevertheless, this
result was not observed in our study, it is possible that
such a finding is attributable to relatively small numbers
of subjects in the cohort.
It is widely accepted that both host and virus factors
can influence the SVR[7,24]. Ge et al. reported that
among Caucasian patients with G1, the rs12979860 (3
kilobases upstream of the IL-28B gene) wild CC geno-
type was an independent predictor favoring SVR [10].
McCarthy et al. demonstrated a similar finding with re-
spect to off-treatment viral loads in Caucasian patients
with G1 [25]. Our study included 47% non-G1 infectedpatients, and surprisingly, the percent of patients with a
favorable IL-28B genotype was higher in the non-G1
group (77.9%). There is the possibility that the
rs8099917 TT genotype may help select patients with
non-G1 infections. The influence of host genotype could
be slightly stronger among individuals infected by the
non-G1 than among those infected by the G1. We found
that G1 infected patients had an increased risk of NVR
and REL than non-G1, and this data generated from the
current study could provide important information for
patients who either would or would not benefit from
PEG-IFN-α/RBV treatment before starting treatment.
However, these results need additional confirmation in
other cohorts.
It is anticipated that this study, which identified a
highly genetic association between NVR and REL in
patients with different viral genotypes, will have a lasting
impact, particularly in the development of individualized
treatment strategies. Also, the higher frequency of the
TT genotype in Chinese patients may explain (at least
partially) why Chinese patients have superior responses
to PEG-IFN-α/RBV therapy than other nationalities. The
strong associations between IL-28B (rs8099917) geno-
types and SVR are consistent in different ethnic groups
[10]. The IL-28B genotype may guide clinical decision
making regarding whether or not to initiate therapy,
how long to continue therapy for avoiding unpleasant
side effects associated with treatment. Nevertheless,
there are also NVR (9.1%) and REL (13.0%) patients,
even when the favorable TT genotype and non-G1 was
identified in patients included in the current study.
These results indicate that further prospective studies
comparing the treatment efficacy are warranted.
The major limitation of this study is the small number
of included cases resulting in low statistical power. Fur-
ther, whether or not geographic variations in the HCV
core protein mutations in the interferon sensitivity-
determining region contribute to a relatively much
higher SVR rate in the current study remains uncertain
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HCV genotype frequencies and IL-28B genotypes be-
tween individuals with either cleared or chronic infec-
tion because samples from the acute phase of HCV
infection were unavailable in individuals with spontan-
eous HCV clearance.
Conclusion
In conclusion, host genetic polymorphisms rs8099917 in
the vicinity of IL-28B is the most important predictor of
treatment response of PEG-IFN-α/RBV for Chinese
HCV patients. Furthermore, viral genotype testing prior
to HCV therapy could provide important information




The study protocol was approved by the institutional re-
view boards of Sun Yat-Sen University. Written informed
consent was obtained from each participant after a full
explanation of the study.
We retrospectively recruited 236 patients from Chinese
with CHC and different HCV genotype infection who
underwent the current standard-of-care regimens be-
tween 2006 and 2010 in the outpatient clinic of the Third
Affiliated Hospital of Sun Yat-Sen University. The diag-
noses of CHC were based on previously described criteria
[28]. The patients were positive for anti-HCV antibody
and serum HCV RNA for > 6 months. All eligibale sub-
jects were treated with PEG-IFN-α-2a at a fixed dose of
180 μg/week and ribavirin 800–1,200 mg/day (i.e., 800
mg for patients <65 kg; 1,000 mg for patients weighing
65 to 85 kg; 1,200 mg for patients weighing 85 to 105
kg). Patients with genotype 1 and 6 were treated for 48
weeks and patients with genotype 2 or 3 were treated for
24 weeks. Quantitative HCV RNA(Cobas Amplicor
Hepatitis C Virus Test, V.2.0; Roche Diagnostics,
Branchburg, New Jersey, USA; detection limit: 50 IU/mL)
and alanine aminotransferase(ALT) levels were evaluated 4,
12, 48, and 72 weeks after the start of anti-viral therapy. An
autoimmune panel and thyroid function tests were per-
formed every 3 months during treatment. After completing
the therapy, the patients were followed- up for 24 weeks
and the therapeutic effectiveness was evaluated. Patients
who withdraw from therapy due to undesirable side effects
were excluded. Patients included in the SVR group
had normal ALT levels and no evidence of viremia
24 weeks after completion of IFN therapy). Those
included in the NVR group had HCV RNA levels
detectable during the completed period of the treat-
ment, and patients in the REL group had HCV RNA
reappearance during the follow-up period but who
had initially achieved an end-of-treatment virologicalresponse. In total, 101 patients had ultrasound-
guided percutaneous liver biopsies. All biopsy speci-
mens were used for the histologic diagnosis. Disease
staging was defined according to Desmet [11,29] with
ranking from F0 (absence of fibrosis) to F4 (cirrhosis stage).Genomic DNA isolation
Blood was collected in EDTA tubes using standard proce-
dures. Genomic DNA was extracted from 200 μL of the cell
suspension with Omega kits (Omega-Tek, Mansfield, OH,
USA). All DNA preparations were stored at −70 °C until
further use.Polymerase chain reaction (PCR) and rs8099917 SNP
genotyping
The PCR bands of interest were excised from agarose
gel, and the DNA fragments were purified with gel ex-
traction kits (Omega-Tek). The purified fragments were
sequenced with rs8099917 sense (5'-CCCACTTCTG
GAACAAATCGTCCC-3) and rs8099917 antisense (5'-
TCAACCCCACCTCAAATTATCCTA-3') sequencing
primers from Shanghai Invitrogen Biotechnology Co.,
Ltd. (Beijing, China). The genotypes of the patients were
determined using ABI TaqMan SNP genotyping assays
(Applied Biosystems, Foster City, CA, USA). Allele dis-
crimination was achieved by detecting fluorescence
using System SDS software (Applied Biosystems, Foster
City, CA, USA).Statistical analysis
Frequencies were compared between groups using either a
chi-square test with the Yates correction or the Fisher exact
test. Group means, presented as mean values and standard
deviations, were compared using analysis of variance and
the Student’s t-test or Mann–Whitney U test. Serum HCV
RNA levels were expressed after logarithmic transformation
of original values. To assess the relative contribution of pre-
dictors of NVR and REL, the odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated. Statistical
analyses were performed using the SPSS 13.0 statistical
package (SPSS, Inc., Chicago, IL, USA). All statistical ana-
lyses were based on two-sided hypothesis tests with a sig-
nificance level at p <0.05.
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